Teva to pay $225M to settle ldl cholesterol drug price-fixing prices
The generic drug maker Teva Pharmaceuticals agreed Monday to pay $225 million to settle price-fixing prices associated to gross sales of a serious cholesterol-lowering drug. The U.S. Department of Justice mentioned the settlement additionally requires Teva to divest its enterprise making and promoting the drug, pravastatin, a generic model of the brand-name medication Pravachol.
...










